Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RD047-26 · 1 trial · 2 indications
Investigator Global Assessment of Atopic Dermatitis Severity
| Arm | Type | Description |
|---|---|---|
| RD047-26 | EXPERIMENTAL | Study Device |
| Name | Type | Description |
|---|---|---|
| RD047-26 | DEVICE | RD047-26 emollient gel |
Inclusion Criteria: * Written informed consent * Female or male, 18 to 65 years of age and in good general health * Clinical diagnosis of stable mild to moderate atopic dermatitis * Willing and able to follow study instructions and likely to complete all study requirements Exclusion Criteria: * S...
Top 20 of 25 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 9 | PHASE3 | Upadacitinib, corticosteroids |
| Pfizer Inc. | PFE | 11 | PHASE3 | Abrocitinib |
| Eli Lilly and Company | LLY | 4 | PHASE3 | Lebrikizumab, Corticosteroid |
| Sanofi SA Sponsored ADR | SNY | 13 | PHASE3 | Amlitelimab |
| Regeneron Pharmaceuticals, Inc. | REGN | 4 | PHASE3 | Dupilumab |
| Incyte Corporation | INCY | 3 | PHASE3 | Ruxolitinib, Vehicle |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof, 1%, Vehicle |
| Apogee Therapeutics, Inc. | APGE | 3 | PHASE2 | APG777 |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | GIA632 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Corvus Pharmaceuticals, Inc. | CRVS | 1 | PHASE2 | Soquelitinib |
| Nektar Therapeutics | NKTR | 1 | PHASE2 | Rezpegaldesleukin |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE2 | Barzolvolimab |
| Evommune, Inc. | EVMN | 1 | PHASE2 | EVO756 |
| Sunshine Biopharma Incorporated | SBFM | 3 | PHASE3 | 611, corticosteroid |
| Aclaris Therapeutics, Inc. | ACRS | 1 | PHASE2 | ATI-045 |
| Q32 Bio Inc | QTTB | 1 | PHASE2 | ADX-914 |
| Turn Therapeutics Inc. | TTRX | 1 | PHASE2 | GX-03 |
| Arcutis Biotherapeutics Inc | ARQT | 1 | PHASE1 | ARQ-234 |
RD047-26 is an investigational drug being studied for the treatment of mild to moderate atopic dermatitis in adults. It is also being evaluated for its effects on pruritus, or itching, associated with the condition. The drug is currently in Phase 2 clinical development.
RD047-26 is being developed by Sonoma Pharmaceuticals, Inc., a company traded on the NASDAQ under the ticker symbol SNOA. The company is conducting clinical research on this drug for the treatment of atopic dermatitis.
RD047-26 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied for safety and efficacy in clinical trials.
RD047-26 has been studied in a completed Phase 2 clinical trial with the identifier NCT01232985. This trial evaluated the efficacy and tolerability of RD047-26 for the treatment of mild to moderate atopic dermatitis in adults, enrolling 17 participants in the United States.
RD047-26 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development. The completed clinical trial for this drug was an uncontrolled study, and further research would be needed to establish its safety and efficacy for regulatory approval.